One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum. Corcept posted revenue of $207.6 million, up 13.7% year-over-year, with net income of $19.4 million. Amicus reported revenue of $169.1 million, up 19.5%, while turning a quarterly profit of $17.3 million after years of losses.
Corcept Slows Down. Amicus Speeds Up.
Corcept built its business on Korlym, a cortisol modulation therapy for Cushing’s syndrome and related metabolic disorders. The product delivers gross margins of 97.8%, but the company burns cash on SG&A ($124 million) and R&D ($69 million) to support pipeline expansion. Operating margin sits at 4.9%, and annual earnings growth collapsed 61% year-over-year despite the revenue bump. The company trades at 42.6x trailing earnings, stretched given the growth deceleration.
Amicus relies on enzyme replacement therapies for lysosomal storage disorders, a narrower but faster-growing market. Its operating margin of 20.3% dwarfs Corcept’s, even though gross margins are lower at 87.4%. The company carries $392 million in long-term debt but just crossed into profitability after 18 consecutive years of losses. Revenue growth of 19.5% outpaces Corcept’s, and the company beat Q3 estimates by 100% ($0.06 actual versus $0.03 expected).
| Metric | CORT | FOLD |
| Revenue Growth (YoY) | 13.7% | 19.5% |
| Operating Margin | 4.9% | 20.3% |
| Gross Margin | 97.8% | 87.4% |
| Debt Load | Minimal | $392M long-term |
One Defends Turf. One Chases Expansion.
Corcept’s strategy centers on protecting Korlym’s dominant position while advancing its cortisol modulation platform into oncology and psychiatry. The company holds $399 million in investments and $125 million in cash, giving it flexibility to fund trials without tapping debt markets. But insider activity tells a cautious story. CEO Joseph Belanoff exercised 550,000 options at $3.88 on December 24, then immediately sold 306,846 shares at $83.59 the same day. Chief Development Officer William Guyer executed three separate exercise-and-sell cycles since November, acquiring at $21.65 and selling at $74 to $83. This pattern suggests executives are locking in gains, not betting on near-term upside.
Amicus focuses on expanding its enzyme therapy portfolio and improving supply chain efficiency. The company carries $178 million in inventory versus Corcept’s $12 million, reflecting a more complex manufacturing footprint. Management sold heavily into strength in early January, with four C-suite executives disposing of 153,278 shares at $14.27 after the stock recovered from $5.13 lows in November. That 178% recovery created an exit opportunity, and leadership took it.
Which Fits Your Portfolio Better?
If you want a proven, cash-generating business with minimal debt, Corcept fits that profile. But the 42.6x P/E and slowing earnings growth make it expensive. Analysts see upside to $91, but insider selling at $80-plus suggests management thinks the current price is fair.
Amicus offers a turnaround story with faster revenue growth and improving margins. The debt load is manageable if profitability holds, and the valuation is more reasonable given the growth trajectory. I would lean toward Amicus if you believe the profitability inflection is sustainable. Corcept makes more sense if you prioritize balance sheet strength and are willing to pay a premium for stability.
Contact [email protected] for any questions or corrections.






